patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_447915 | REC_0007401 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 12.2 | 68 | female | 0 | 15 | 6.1 | 0 | osimertinib 80 mg daily | 21.4 | true | MSS | 2026-03-15T05:35:58.667139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737762 | REC_0007402 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 14 | 74 | female | 1 | 19 | 5.3 | 1 | entrectinib 600 mg daily | 16.3 | false | MSI-H | 2026-03-15T05:35:58.667369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822803 | REC_0007403 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 34 | 11.2 | 54 | female | 0 | 14 | 5.2 | 2 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:58.667606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528128 | REC_0007404 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 14.7 | 60 | male | 1 | 8 | 5.1 | 7 | alectinib 600 mg BID | 12.8 | false | MSS | 2026-03-15T05:35:58.667839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557152 | REC_0007405 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 11.8 | 61 | female | 1 | 5 | 7.3 | 5 | sotorasib 960 mg daily | 10.4 | true | MSI-H | 2026-03-15T05:35:58.668096+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490897 | REC_0007406 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 33 | 7.1 | 71 | female | 2 | 30 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.6 | false | MSS | 2026-03-15T05:35:58.668329+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773525 | REC_0007407 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 5.1 | 76 | female | 3 | 36 | 6.2 | 7 | pembrolizumab 200 mg q3w | 5.9 | true | MSS | 2026-03-15T05:35:58.668562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535436 | REC_0007408 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 15.3 | 74 | female | 1 | 19 | 6.5 | 8 | sotorasib 960 mg daily | 11.3 | false | MSI-H | 2026-03-15T05:35:58.668792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613185 | REC_0007409 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 11.3 | 75 | female | 2 | 17 | 5.7 | 2 | entrectinib 600 mg daily | 22.1 | true | MSS | 2026-03-15T05:35:58.669025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215773 | REC_0007410 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 18.4 | 70 | male | 1 | 18 | 5.3 | 2 | alectinib 600 mg BID | 11 | false | MSI-H | 2026-03-15T05:35:58.669259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434111 | REC_0007411 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 16.8 | 70 | female | 3 | 11 | 5.3 | 8 | osimertinib 80 mg daily | 19.4 | true | MSS | 2026-03-15T05:35:58.669532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450919 | REC_0007412 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 31 | 16.2 | 70 | female | 2 | 14 | 5.9 | 2 | pembrolizumab 200 mg q3w | 15.3 | false | MSI-H | 2026-03-15T05:35:58.669771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285576 | REC_0007413 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 31 | 10.5 | 69 | female | 1 | 9 | 4.3 | 3 | pembrolizumab 200 mg q3w | 6.9 | false | MSI-H | 2026-03-15T05:35:58.670006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_595389 | REC_0007414 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 6.8 | 73 | female | 1 | 12 | 6 | 1 | alectinib 600 mg BID | 19.6 | true | MSS | 2026-03-15T05:35:58.670235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608127 | REC_0007415 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 8.4 | 72 | male | 3 | 13 | 5.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.2 | true | MSS | 2026-03-15T05:35:58.670468+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566861 | REC_0007416 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 10.3 | 83 | female | 1 | 9 | 4 | 4 | sotorasib 960 mg daily | 12.3 | true | MSI-H | 2026-03-15T05:35:58.670698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220362 | REC_0007417 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 5.6 | 68 | male | 1 | 14 | 4.9 | 2 | pembrolizumab 200 mg q3w | 17.1 | false | MSS | 2026-03-15T05:35:58.670931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342005 | REC_0007418 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 13.8 | 77 | female | 2 | 10 | 5.1 | 1 | entrectinib 600 mg daily | 8.9 | false | MSS | 2026-03-15T05:35:58.671163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637028 | REC_0007419 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 13.2 | 77 | female | 2 | 17 | 8.5 | 1 | alectinib 600 mg BID | 12.8 | true | MSS | 2026-03-15T05:35:58.671396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521819 | REC_0007420 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 14.1 | 69 | female | 0 | 18 | 7.7 | 7 | osimertinib 80 mg daily | 7 | true | MSI-H | 2026-03-15T05:35:58.671629+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360254 | REC_0007421 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.8 | 60 | female | 1 | 13 | 7.6 | 5 | pembrolizumab 200 mg q3w | 13.1 | false | MSS | 2026-03-15T05:35:58.671863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764876 | REC_0007422 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 13 | 69 | female | 0 | 10 | 3.8 | 2 | osimertinib 80 mg daily | 18.2 | true | MSI-H | 2026-03-15T05:35:58.672121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558409 | REC_0007423 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 5.8 | 48 | female | 0 | 23 | 3.9 | 9 | sotorasib 960 mg daily | 14.4 | false | MSS | 2026-03-15T05:35:58.672356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717659 | REC_0007424 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 6.8 | 59 | female | 1 | 61 | 4.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 28.1 | false | MSS | 2026-03-15T05:35:58.672637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563303 | REC_0007425 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 10.2 | 74 | female | 0 | 15 | 4.9 | 6 | sotorasib 960 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:35:58.672877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566864 | REC_0007426 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 15.8 | 72 | female | 1 | 24 | 4.5 | 9 | sotorasib 960 mg daily | 14.9 | false | MSS | 2026-03-15T05:35:58.673110+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971033 | REC_0007427 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 9.4 | 62 | male | 1 | 17 | 5.7 | 5 | osimertinib 80 mg daily | 12 | false | MSS | 2026-03-15T05:35:58.673343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406788 | REC_0007428 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 11.6 | 77 | male | 1 | 14 | 6.9 | 1 | pembrolizumab 200 mg q3w | 20.9 | false | MSI-H | 2026-03-15T05:35:58.673579+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951220 | REC_0007429 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 19.8 | 66 | male | 1 | 23 | 4.5 | 5 | sotorasib 960 mg daily | 4.4 | false | MSI-H | 2026-03-15T05:35:58.673817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248445 | REC_0007430 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 11.8 | 76 | female | 1 | 17 | 5.2 | 6 | alectinib 600 mg BID | 11.8 | true | MSI-H | 2026-03-15T05:35:58.674054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281479 | REC_0007431 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 5.8 | 55 | female | 0 | 45 | 4.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 29.1 | true | MSS | 2026-03-15T05:35:58.674288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_266071 | REC_0007432 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 9.2 | 52 | female | 0 | 21 | 5.3 | 1 | entrectinib 600 mg daily | 17.1 | true | MSS | 2026-03-15T05:35:58.674521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562455 | REC_0007433 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.6 | 62 | male | 0 | 7 | 6.4 | 5 | entrectinib 600 mg daily | 9 | true | MSS | 2026-03-15T05:35:58.674757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_798339 | REC_0007434 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 26 | 5.1 | 71 | male | 2 | 20 | 5.2 | 0 | carboplatin + paclitaxel + pembrolizumab | 35.7 | false | MSS | 2026-03-15T05:35:58.674986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303158 | REC_0007435 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 9.8 | 57 | male | 1 | 14 | 5 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.675220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485936 | REC_0007436 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 5.5 | 68 | female | 1 | 25 | 7 | 4 | pembrolizumab 200 mg q3w | 8.2 | true | MSS | 2026-03-15T05:35:58.675444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271688 | REC_0007437 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 5.7 | 69 | female | 0 | 7 | 6.2 | 5 | pembrolizumab 200 mg q3w | 8 | false | MSS | 2026-03-15T05:35:58.675717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_908390 | REC_0007438 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 12.3 | 84 | male | 1 | 23 | 7.5 | 3 | entrectinib 600 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:58.675957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594652 | REC_0007439 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 10.7 | 72 | male | 2 | 7 | 6.4 | 3 | sotorasib 960 mg daily | 29.6 | true | MSS | 2026-03-15T05:35:58.676316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255215 | REC_0007440 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 14.5 | 53 | male | 0 | 22 | 5.6 | 6 | osimertinib 80 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:58.676560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995588 | REC_0007441 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 13.2 | 51 | male | 0 | 10 | 5.2 | 5 | alectinib 600 mg BID | 12 | false | MSS | 2026-03-15T05:35:58.676796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740654 | REC_0007442 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 17.2 | 67 | female | 0 | 23 | 5.4 | 1 | sotorasib 960 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:58.677030+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402630 | REC_0007443 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 19 | 4.9 | 62 | male | 1 | 3 | 5.2 | 1 | pembrolizumab 200 mg q3w | 10.9 | true | MSS | 2026-03-15T05:35:58.677263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_770506 | REC_0007444 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 15.2 | 68 | female | 0 | 19 | 6.5 | 1 | osimertinib 80 mg daily | 16.4 | true | MSS | 2026-03-15T05:35:58.677497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964525 | REC_0007445 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 12.9 | 62 | male | 0 | 12 | 6.6 | 2 | sotorasib 960 mg daily | 27 | true | MSS | 2026-03-15T05:35:58.677733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620928 | REC_0007446 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 13.8 | 54 | male | 0 | 19 | 5.3 | 4 | entrectinib 600 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:58.677965+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529517 | REC_0007447 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 7.2 | 63 | female | 1 | 36 | 4.2 | 7 | pembrolizumab 200 mg q3w | 8.8 | true | MSS | 2026-03-15T05:35:58.678199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878584 | REC_0007448 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 12.1 | 57 | female | 0 | 20 | 4.9 | 3 | osimertinib 80 mg daily | 12.6 | true | MSI-H | 2026-03-15T05:35:58.678434+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936229 | REC_0007449 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 5.9 | 63 | female | 1 | 21 | 6.7 | 4 | osimertinib 80 mg daily | 14.9 | true | MSS | 2026-03-15T05:35:58.678665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233256 | REC_0007450 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 12.1 | 49 | female | 0 | 9 | 4.8 | 3 | osimertinib 80 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:58.678945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264541 | REC_0007451 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 5.7 | 60 | female | 0 | 68 | 2.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 9.6 | false | MSS | 2026-03-15T05:35:58.679188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_907824 | REC_0007452 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 15.2 | 49 | female | 0 | 10 | 5 | 4 | pembrolizumab 200 mg q3w | 15.1 | false | MSI-H | 2026-03-15T05:35:58.679434+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998043 | REC_0007453 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 8.3 | 69 | female | 1 | 21 | 4.6 | 3 | alectinib 600 mg BID | 9 | true | MSS | 2026-03-15T05:35:58.679684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183213 | REC_0007454 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 14.6 | 75 | female | 2 | 6 | 5.6 | 6 | entrectinib 600 mg daily | 7.2 | true | MSI-H | 2026-03-15T05:35:58.679918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148552 | REC_0007455 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 16.7 | 71 | female | 2 | 17 | 5.5 | 2 | osimertinib 80 mg daily | 26.8 | false | MSI-H | 2026-03-15T05:35:58.680340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462837 | REC_0007456 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 14.9 | 81 | female | 1 | 17 | 4.5 | 3 | osimertinib 80 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:35:58.680619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984669 | REC_0007457 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 9 | 64 | male | 1 | 25 | 7 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.9 | true | MSS | 2026-03-15T05:35:58.680868+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536483 | REC_0007458 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 32 | 8.8 | 48 | female | 0 | 22 | 7.1 | 0 | alectinib 600 mg BID | 54.5 | false | MSS | 2026-03-15T05:35:58.681106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202126 | REC_0007459 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 8.1 | 62 | male | 1 | 12 | 6 | 1 | pembrolizumab 200 mg q3w | 14.4 | true | MSS | 2026-03-15T05:35:58.681344+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584089 | REC_0007460 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 4.1 | 67 | female | 0 | 10 | 5.2 | 6 | alectinib 600 mg BID | 13.2 | false | MSS | 2026-03-15T05:35:58.681576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697521 | REC_0007461 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 18.4 | 57 | female | 1 | 14 | 4.4 | 7 | osimertinib 80 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:35:58.681817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511083 | REC_0007462 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7.2 | 72 | female | 1 | 70 | 5.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 15.5 | false | MSS | 2026-03-15T05:35:58.682048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613826 | REC_0007463 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 32 | 7.2 | 65 | male | 1 | 18 | 6 | 1 | pembrolizumab 200 mg q3w | 17.2 | false | MSS | 2026-03-15T05:35:58.682390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456983 | REC_0007464 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 7.4 | 56 | female | 1 | 27 | 3.1 | 5 | pembrolizumab 200 mg q3w | 8.1 | true | MSS | 2026-03-15T05:35:58.682632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458939 | REC_0007465 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 2.5 | 82 | female | 2 | 2 | 4.2 | 8 | pembrolizumab 200 mg q3w | 11.6 | true | MSS | 2026-03-15T05:35:58.682863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564614 | REC_0007466 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 19.3 | 60 | female | 1 | 12 | 4.2 | 8 | alectinib 600 mg BID | 4.1 | false | MSI-H | 2026-03-15T05:35:58.683098+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698251 | REC_0007467 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 9.5 | 71 | female | 2 | 14 | 6.9 | 1 | pembrolizumab 200 mg q3w | 15.1 | false | MSS | 2026-03-15T05:35:58.683332+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285290 | REC_0007468 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 5.1 | 67 | male | 1 | 33 | 5.2 | 2 | pembrolizumab 200 mg q3w | 17.7 | true | MSS | 2026-03-15T05:35:58.683566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520099 | REC_0007469 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.8 | 65 | male | 1 | 19 | 6.1 | 5 | pembrolizumab 200 mg q3w | 14 | true | MSS | 2026-03-15T05:35:58.683798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392652 | REC_0007470 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 35 | 12.2 | 82 | female | 1 | 27 | 6.5 | 1 | pembrolizumab 200 mg q3w | 23.1 | false | MSI-H | 2026-03-15T05:35:58.684032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364731 | REC_0007471 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11.8 | 57 | male | 0 | 18 | 4.9 | 5 | entrectinib 600 mg daily | 12.6 | true | MSI-H | 2026-03-15T05:35:58.684552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224895 | REC_0007472 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 16.1 | 53 | female | 0 | 5 | 4.6 | 3 | osimertinib 80 mg daily | 18.3 | false | MSS | 2026-03-15T05:35:58.684799+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227085 | REC_0007473 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 4.7 | 53 | male | 0 | 23 | 4.8 | 1 | osimertinib 80 mg daily | 12.4 | true | MSS | 2026-03-15T05:35:58.685036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423852 | REC_0007474 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11.6 | 81 | female | 2 | 18 | 6.1 | 7 | alectinib 600 mg BID | 15.7 | true | MSI-H | 2026-03-15T05:35:58.685271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_299192 | REC_0007475 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 10.9 | 66 | female | 1 | 20 | 5.6 | 5 | sotorasib 960 mg daily | 7.3 | false | MSS | 2026-03-15T05:35:58.685504+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113767 | REC_0007476 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 6.7 | 74 | female | 2 | 23 | 4.3 | 8 | sotorasib 960 mg daily | 7 | false | MSS | 2026-03-15T05:35:58.685821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_911331 | REC_0007477 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 18.7 | 63 | female | 0 | 22 | 6.9 | 5 | osimertinib 80 mg daily | 11 | true | MSI-H | 2026-03-15T05:35:58.686061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215243 | REC_0007478 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 13.6 | 75 | female | 1 | 10 | 5.3 | 2 | alectinib 600 mg BID | 22.1 | false | MSI-H | 2026-03-15T05:35:58.686298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574142 | REC_0007479 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 16 | 7.6 | 63 | female | 0 | 68 | 4.7 | 6 | pembrolizumab 200 mg q3w | 11.5 | false | MSS | 2026-03-15T05:35:58.686534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782771 | REC_0007480 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 10.6 | 57 | male | 1 | 13 | 6 | 1 | osimertinib 80 mg daily | 25.8 | false | MSI-H | 2026-03-15T05:35:58.686772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229817 | REC_0007481 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 12.4 | 62 | male | 1 | 20 | 4.6 | 2 | alectinib 600 mg BID | 13.3 | true | MSS | 2026-03-15T05:35:58.687008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916488 | REC_0007482 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 4.1 | 73 | male | 2 | 24 | 5.5 | 1 | sotorasib 960 mg daily | 13.9 | false | MSS | 2026-03-15T05:35:58.687240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575621 | REC_0007483 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 12.1 | 69 | male | 0 | 20 | 3.3 | 4 | osimertinib 80 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:58.687477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887300 | REC_0007484 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 10.7 | 59 | female | 1 | 20 | 6.5 | 4 | sotorasib 960 mg daily | 15 | false | MSI-H | 2026-03-15T05:35:58.687710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977348 | REC_0007485 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 7.1 | 61 | female | 1 | 18 | 4.5 | 5 | sotorasib 960 mg daily | 5.6 | false | MSS | 2026-03-15T05:35:58.687944+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924342 | REC_0007486 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.7 | 63 | female | 0 | 99 | 5.6 | 3 | carboplatin + paclitaxel + pembrolizumab | 11.9 | true | MSS | 2026-03-15T05:35:58.688263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222584 | REC_0007487 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 18.5 | 67 | male | 1 | 23 | 5.9 | 6 | alectinib 600 mg BID | 7.6 | true | MSI-H | 2026-03-15T05:35:58.688508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870982 | REC_0007488 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 4.9 | 82 | female | 1 | 53 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 23.9 | false | MSS | 2026-03-15T05:35:58.688739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902070 | REC_0007489 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 30 | 3.8 | 66 | female | 1 | 83 | 6 | 1 | pembrolizumab 200 mg q3w | 5.3 | true | MSS | 2026-03-15T05:35:58.689028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493026 | REC_0007490 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 12.8 | 62 | female | 0 | 12 | 7 | 6 | entrectinib 600 mg daily | 8.6 | false | MSI-H | 2026-03-15T05:35:58.689267+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655229 | REC_0007491 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 14.8 | 75 | female | 2 | 21 | 5.8 | 6 | sotorasib 960 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:58.689499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982570 | REC_0007492 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 26 | 9.7 | 63 | male | 0 | 5 | 5.2 | 0 | alectinib 600 mg BID | 39.7 | false | MSS | 2026-03-15T05:35:58.689733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457433 | REC_0007493 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 10.3 | 67 | female | 1 | 21 | 5.1 | 1 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:58.689971+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972097 | REC_0007494 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 8 | 67 | female | 1 | 13 | 5.8 | 1 | alectinib 600 mg BID | 27.2 | false | MSS | 2026-03-15T05:35:58.690205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772465 | REC_0007495 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 12.6 | 67 | female | 0 | 23 | 3.1 | 6 | sotorasib 960 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:58.690440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918783 | REC_0007496 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 13 | 58 | male | 1 | 16 | 4.7 | 8 | alectinib 600 mg BID | 12 | false | MSS | 2026-03-15T05:35:58.690676+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525043 | REC_0007497 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 13 | 15.2 | 59 | female | 0 | 19 | 5.2 | 2 | osimertinib 80 mg daily | 22.1 | false | MSI-H | 2026-03-15T05:35:58.690913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455221 | REC_0007498 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 7.6 | 69 | female | 0 | 71 | 7.5 | 6 | pembrolizumab 200 mg q3w | 15.2 | false | MSS | 2026-03-15T05:35:58.691141+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852974 | REC_0007499 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.1 | 62 | male | 1 | 54 | 4.8 | 6 | pembrolizumab 200 mg q3w | 11 | true | MSS | 2026-03-15T05:35:58.691373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131239 | REC_0007500 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 11 | 11.4 | 75 | male | 1 | 13 | 5.2 | 5 | sotorasib 960 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:58.691611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.